About Us
The UW Small Molecule Screening Facility (SMSF) and Medicinal Chemistry Core Facility (MCCF) is a fully equipped high throughput screening facility (HTS) offering expert staff and instrumentation for HTS of over 100,000 small molecules and the DHARMACON smartpool RNAi library of short interfering RNAs. The SMSF also offers custom mechanism of action assays on user provided compounds. The Medicinal Chemistry Core Facility offers consulting, scale-up synthesis, generation of structure activity relationship libraries, natural product fractionation, molecular modeling and compound analytical services.
Information
Click a section header to expand or collapse it's content.
News
January 28th, 2010
NIDA seeks development and implementation High Throughput Screening (HTS) assays for nicotinic receptors containing alpha3, alpha5, and beta4 subunits
As part of the NIH Molecular Libraries initiative http://mli.nih.gov/mli/, the National Institute on Drug Abuse (NIDA) is interested in developing new and soliciting existing High Throughput Screening (HTS) assays for nicotinic receptors containing alpha3, alpha5, beta4 receptor subunits. Genome wide association studies (GWAS) have implicated nicotinic receptors containing these subunits in tobacco dependence and in the consequences of tobacco dependence (e.g., lung cancer).
If you have an HTS-ready assay with these subunits, NIDA encourages you to submit an application under “Solicitation of Assays for High Throughput Screening (HTS) in the Molecular Libraries Probe Production Centers Network (MLPCN) (R03)” http://grants.nih.gov/grants/guide/pa-files/PAR-09-129.html. Selected HTS assays will be given access to an NIH-supported Molecular Libraries Probe Production Center where the assay will be screened against over 300,000 chemical compounds at no cost to the assay provider. In addition, you can receive up to $50,000 in direct cost to cover assay implementation (e.g. purchase of non-commercially available reagents, travel to the screening centers).
If you seek to develop an HTS assay for these nicotinic receptor subunits from a cell based assay, please refer to http://grants.nih.gov/grants/guide/pa-files/PAR-08-024.html “Assay Development for High Throughput Molecular Screening (R21). This PAR supports development and adaptation of biological assays for use in HTS projects. Once HTS ready, the NIH Molecular Libraries Production Centers Network (MLPCN) can screen the assay against over 300,000 active compounds at no cost to the assay provider. The final receipt date for PAR-09-024 is March 20, 2010.
If you already have a HTS assay as part of a peer reviewed NIH application, you may submit a fast track proposal to the molecular libraries screening centers that will be administratively reviewed (see http://grants.nih.gov/grants/guide/notice-files/NOT-RM-09-011.html) and if approved, it will be screened against the NIH chemical library of over 300,000 compounds at no cost to the assay provider.
Before submitting an application it is suggested that investigators contact
Ananth V Charya
Office of the Director
National Institute on Drug Abuse
6001 Executive Blvd. Rm 4248
Bethesda, MD 20892-9555
Phone: 301-435-1692
Fax: 301-594-6043Email. AnanthCharya@nih.gov
January 26th, 2010
SMSF expands the small collection to over 100,000 compounds. Several new libraries are available for screening - please see our libraries page and contact us for more information : 608-265-9687, hts@uwccc.wisc.eduJanuary 9th, 2010
YOU HAVE ALREADY MADE THE COMPOUNDS, SO LET'S SEE WHAT THEY CAN DO!
The UWCCC Small Molecule Screening Facility (SMSF) and Medicinal Chemistry Core Facility invite you to submit your compounds to the UW Discovery Library (UWDL). The purpose of the UWDL Program is to compile a collection of novel UW compounds into a format for high-throughput screening at the SMSF. These compounds may be acquired through synthesis or isolation from natural sources at UW. The UWDL will be accessible to all groups on campus who wish to screen at the SMSF, with the goal of finding new and interesting activities for these compounds. There will be no cost for donating to the UWDL. By simply donating compounds or extracts, providers open the door to alternate avenues of research and potentially fruitful collaborations within the university. The UWDL is intended to seed and expedite discoveries on campus, establish unexpected and unknown connections across scientific disciplines, and inspire collaborations that lead to interdisciplinary research projects and programs.To submit compounds, please contact Frank Kotch: medchem@pharmacy.wisc.edu or 263-2644.
September 29, 2009
The new web template has been put live and is ready for content additions from the staff. If you are trying to access the old website, please visit hts.wisc.edu/oldsite.
August 20, 2009
Big changes have been made to the layout of the web design -- now featuring a broader use of jQuery!
Equipment
Libraries
Publications
Ason B, Reznikoff WS.
A high-throughput assay for Tn5 Tnp-induced DNA cleavage.
Nucleic Acids Res. 2004 Jun 16;32(10):e83.
Soltero-Higgin M, Carlson EE, Phillips JH, Kiessling LL.
Identification of inhibitors for UDP-galactopyranose mutase.
J Am Chem Soc. 2004 Sep 1;126(34):10532-3. No abstract available.
PMID: 15327298 [PubMed - indexed for MEDLINE]
Kim, M, Wessely, V, Lan, Q.
Identification of Mosquito Sterol Carrier Protein-2 Inhibitors
J Lipid Res. 2005 Apr;46(4):650-7. Epub 2005 Jan 1.
Ason B, Knauss DJ, Balke AM, Merkel G, Skalka AM, Reznikoff WS.
Targeting Tn5 transposase identifies human immunodeficiency virus type 1 inhibitors.
Antimicrob Agents Chemother. 2005 May;49(5):2035-43.
Kozlov M, Bergendahl V, Burgess R, Goldfarb A, Mustaev A.
Homogenous fluorescent assay for RNA polymerase
Anal Biochem. 2005 Jul 15;342(2):206-13
Langenhan JM, Peters NR, Guzei IA, Hoffmann FM, Thorson JS.
Enhancing the Anti-Cancer Properties of Cardiac Glycosides via Neoglycorandomization.
Proc Natl Acad Sci U S A. 2005 Aug 30;102(35):12305-10
Rutkoski TJ, Kurten EL, Mitchell JC, Raines RT.
Disruption of Shape-Complementarity Markers to Create Cytotoxic Variants of Ribonuclease A. J Mol Biol. 2005 Sep 23
Zhang C, Albermann C, Fu X, Peters NR, Chisholm JD, Zhang G, Gilbert EJ, Wang PG, Van Vranken DL, Thorson JS.
RebG- and RebM-Catalyzed Indolocarbazole Diversification.
Chembiochem. 2006 Mar 31;7(5):795-804
Carlson EE, May JF, Kiessling LL.
Chemical probes of UDP-galactopyranose mutase.
Chem Biol. 2006 Aug;13(8):825-37.
Ahmed, A., Peters, N.R., Fitzgerald, M.K., Watson, J.A., Hoffmann, F.M., and Thorson, J.S.
Colchicine Glycorandomization Influences Cytotoxicity and Mechanism of Action J. Am. Chem. Soc. , 2006, 10.1021/ja064686s
Links
University of Wisconsin
UW-Madison
UW Comprehensive Cancer Center
McArdle Laboratory for Cancer Research
Hoffmann Lab
Beilstein-Gmelin Crossfire Help
SciFinder Help
UW Chemistry Librarian
UW Pharmaceutical Experiment Station
UW Ebling Library
UW Biotechnology Center
UW Biochemistry Center
UW-Madison Department of Chemistry
WARF
External Screening and Chemistry Resources
Society for Biomolecular Screening
Small Molecule Chemistry Databases/Search Services
Other Screening Facilities
Academy of Finland/Systems Biology and Bioinformatics
Berkeley Molecular Sciences Institute
Case Western Reserve/NIMH Psychoactive Drug Screening Program
Cornell University Nano-biotechnology Center
German Cancer Research Center
Harvard Medical School Institute for Chemistry and Cell Biology
McMaster University
Memorial Sloan Kettering Cancer Center
Michigan High Throughput Screening Center
Rockefeller University High Throughput Screening Facility
Rutgers University
Southern Research Institute
Stanford High Throughput Bioscience Center
University of Alabama Facility
University of Kansas Facility
University of Massachusetts Medical School
Chemical Genomics Laboratories
Stockwell Laboratory





